Key Takeaways
- • Norstella launched the Pipeline-to-Patient Productivity Index (P3i), the first annual benchmark tracking R&D productivity, market access, and commercial returns across the top 25 global biopharma companies across the entire drug development and commercialization lifecycle.
- • Eli Lilly ranked first in the inaugural P3i, rising from a projected 16th place position against 2020 benchmarks, driven by operational improvements across its pipeline rather than GLP-1 franchise success alone.
- • The P3i is enabled by Norstella's integrated data platform combining assets from Citeline, Evaluate, and MMIT, positioning the index as a decision-support tool for capital allocation and portfolio strategy in biopharma R&D.
- • The inaugural report reveals significant inflationary pressures on R&D costs across the sector, addressing a critical gap in performance measurement for an industry making sustained, multi-billion-dollar investments annually.
Summary
Norstella, an AI-enabled pharma intelligence solutions provider, introduced the Pipeline-to-Patient Productivity Index, a comprehensive annual benchmarking tool designed to measure pharmaceutical R&D productivity, market access effectiveness, and commercial return across the world's 25 largest biopharma companies. According to CEO Mike Gallup, the P3i represents the first index to track molecular performance across the complete drug development journey—from initial pipeline disclosure through clinical evaluation, regulatory approval, market access, and final commercial performance.
The index addresses a structural gap in biopharma performance measurement. Pharmaceutical R&D constitutes one of the largest sustained capital investments across any industry, yet the sector had lacked a standardized scorecard for benchmarking end-to-end productivity. The P3i fills this void by integrating proprietary data assets from Citeline, Evaluate, and MMIT—three complementary datasets that together provide comprehensive visibility across the pharma value chain. This consolidated data architecture enables institutional investors, hedge funds, and biopharma executives to make informed capital allocation and portfolio strategy decisions.
Eli Lilly emerged as the top-ranked performer in the inaugural P3i release, a significant position gain from an estimated 16th place ranking under 2020-equivalent methodology. Notably, Norstella attributed Lilly's ascent to broad operational improvements across its development pipeline rather than exclusive reliance on the commercial success of its GLP-1 franchise, suggesting systematic efficiency gains in R&D execution and market penetration.
The inaugural P3i report also surfaced material findings regarding sector-wide cost pressures. The index exposed considerable inflationary pressures on R&D spending across benchmark participants, a data point with strategic implications for industry capital efficiency, drug pricing models, and investor return expectations. These findings provide institutional investors and alternative asset managers with quantitative evidence for stress-testing biopharma portfolio assumptions and reassessing long-term productivity trends in a higher-cost operating environment.
The index addresses a structural gap in biopharma performance measurement. Pharmaceutical R&D constitutes one of the largest sustained capital investments across any industry, yet the sector had lacked a standardized scorecard for benchmarking end-to-end productivity. The P3i fills this void by integrating proprietary data assets from Citeline, Evaluate, and MMIT—three complementary datasets that together provide comprehensive visibility across the pharma value chain. This consolidated data architecture enables institutional investors, hedge funds, and biopharma executives to make informed capital allocation and portfolio strategy decisions.
Eli Lilly emerged as the top-ranked performer in the inaugural P3i release, a significant position gain from an estimated 16th place ranking under 2020-equivalent methodology. Notably, Norstella attributed Lilly's ascent to broad operational improvements across its development pipeline rather than exclusive reliance on the commercial success of its GLP-1 franchise, suggesting systematic efficiency gains in R&D execution and market penetration.
The inaugural P3i report also surfaced material findings regarding sector-wide cost pressures. The index exposed considerable inflationary pressures on R&D spending across benchmark participants, a data point with strategic implications for industry capital efficiency, drug pricing models, and investor return expectations. These findings provide institutional investors and alternative asset managers with quantitative evidence for stress-testing biopharma portfolio assumptions and reassessing long-term productivity trends in a higher-cost operating environment.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.